the aid library

LIST OPTIONS

Filter

4115

Sort by:

Direction:

Download (35)

View PDF (37)

Guidelines for Management of Type 1 Diabetes

Indian Council of Medical Research (2022) CC2

The ICMR type 1 diabetes guidelines come at a time when the SARS-CoV-2 pandemic has disproportionately affected people with diabetes population, exposing them to a high risk for severe illness and mortality. Globally, diabetes was responsible for over fourmillion deaths in the year 2019. It was th... more

Download (33)

View PDF (43)

NCDs and COVID-19

Pan American Health Organization (PAHO) Pan American Health Organization (PAHO) (2022) C_WHO

The webpage from the Pan American Health Organization (PAHO) discusses the heightened risk that individuals with noncommunicable diseases (NCDs)—such as cardiovascular diseases, diabetes, and cancer—face regarding severe illness and mortality from COVID-19. It emphasizes the necessity of informi... more

Download (39)

View PDF (34)

ENT y COVID-19

Pan American Health Organization (PAHO) Pan American Health Organization (PAHO) (2022) C_WHO

Download (37)

View PDF (41)

Preventing the next Pandemic: the Case for Investing in Circulatory Health

Global Coalition for Circulatory Health (2024) CC

The Coronavirus Disease 2019 (COVID-19) has had a continuous and robust impact on world health. The resulting COVID-19 pandemic has had a devastating physical, mental and fiscal impact on the millions of people living with noncommunicable diseases (NCDs), as they have a higher risk of severe illness... more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (105)

View PDF (140)

Guidance on administration of COVID-19 vaccine boosters in Africa
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so... more

Download (218)

View PDF (259)

Myths & COVID-19 Vaccinations
recommended

Mauder, S.; and P. Reijer (2021) CC

Issue Brief no. 16. 20 Sept 2021. Many studies have shown the effectiveness of vaccination against COVID-19 and that it protects against severe illness. A high vaccination rate is needed to combat the pandemic worldwide. Due to misinformation and myths, there is still a great hesitancy to vaccina... more

Download (281)

View PDF (187)

Safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women

World Health Organization WHO (2021) C_WHO

COVID-19 Vaccines: 1 Safety Surveillance 2 Manual While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn... more

Download (113)

View PDF (132)

Management of covid-19: a practical guideline formaternal and newborn health care providers inSub-Saharan Africa

B. N. Ezenwa, I. B. Fajolu, O. R. Akinajo, et al. The Journal of Maternal-Fetal & Neonatal Medicine (2020) CC

COVID-19 is a pandemic that is currently ravaging the world. Infection rate is steadily increasingin Sub-Saharan Africa. Pregnant women and their infants may suffer severe illnesses due to theirlower immunity. This guideline prepares and equips clinicians working in the maternal and new-born section... more

Download (53)

View PDF (50)

Symptom-based screening tool for asthma syndrome among young children in Uganda

Nantanda, R.; Siersma, V.; Ndeezi, G. et al. npj Primary Care Respiratory Medicine (2020) CC

Under-diagnosis of asthma in ‘under-fives’ may be alleviated by improved inquiry into disease history. We assessed a questionnaire-based screening tool for asthma among 614 ‘under-fives’ with severe respiratory illness in Uganda. The questionnaire responses were compared to post hoc consensu... more

Download (168)

View PDF (184)

Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection
recommended

World Health Organization WHO (2021) C_WHO

15 July 2021. This report describes the demographics, clinical presentation, clinical outcomes, and risk factors among people living with HIV (PLHIV) who have been hospitalized for suspected or confirmed COVID-19. The specific objectives of the analysis were to: describe the clinical char... more

Download (74)

View PDF (111)

Action Protocol for Enhanced SARI and ILI Surveillance for COVID-19 in Africa

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C2

March 2020 The number of African Union Member States reporting COVID- 19 cases is increasing and there is a likelihood of community transmission. The WHO recently modified the COVID-19 suspect case definition to include severe acute respiratory infection and advises testing of all severe acute res... more

Download (77)

View PDF (120)

Action Protocol for Enhanced SARI and ILI Surveillance for COVID-19 in Africa (Arabic)

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C2

Download (82)

View PDF (696)

COVID-19 and HIV News

Nam Aidsmap (2020) C2

Coronavirus and HIV. The impact of the new coronavirus pandemic on people with HIV, sexual health and HIV services. The new virus is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while the illness it causes is coronavirus disease 2019 (COVID-19).

Download (85)

View PDF (127)

Advisory for quarantine of migrant workers

Ministery of Health and Family Welfare - Government of India (2020) C2

Coronavirus disease 2019 (COVID-19) is an acute infectious respiratory disease caused by a newly discovered coronavirus (SARS-CoV-2). Most people infected with the COVID-19 virus experience mild to moderate respiratory illness and recover without requiring special treatment, the disease presentati... more

Download (77)

View PDF (912)

OpenWHO: Introduction to COVID-19 video in Indian Sign Language

World Health Organization WHO (2020) C1

This course consists of a video which provides an introduction to COVID-19 in Indian Sign Language. Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Res... more

Download (371)

View PDF (956)

Risk Communication and Community Engagement Considerations: Ebola Response in Democratic Republic of the Congo

World Health Organization WHO (2018) C_WHO

Overview: Risk communication and community engagement are essential for any disease outbreak response. This is particularly critical during outbreaks of Ebola which may create fear in the public and frontline responders alike due to severe presentation of symptoms, misunderstanding of the causes of ... more

Download (224)

View PDF (263)

Clinical management of COVID-19: Living guideline, 15 September 2022
recommended

World Health Organization WHO (2022) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is ... more

Download (107)

View PDF (154)

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

Download (287)

View PDF (1011)

The social and cultural aspects of mental health in African societies

Mary Amuyunzu-Nyamongo Commonwealth Health Partnerships (2013) C2

The World Health Organization (WHO) defines mental health as ‘a state of well-being in which the individual realizes his or her own abilities, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to his or her community’. Mental illn... more

Guidance on administration of COVID-19 vaccine boosters in Africa recommended

Myths & COVID-19 Vaccinations recommended

Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection recommended

Clinical management of COVID-19: Living guideline, 15 September 2022 recommended

Guidance on administration of COVID-19 vaccine boosters in Africa
recommended

Myths & COVID-19 Vaccinations
recommended

Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection
recommended

Clinical management of COVID-19: Living guideline, 15 September 2022
recommended